MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways

Cancer Letters

Volumn 371, Issue 2, 2016, Pages 171-181

  Xu, Yanmin ^a   Huang, Ji ^a   Ma, Leina ^a   Shan, Juanjuan ^a   Shen, Junjie ^a   Yang, Zhi ^a   Liu, Limei ^a   Luo, Yongli ^a   Yao, Chao ^a   Qian, Cheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Hepatocellular carcinoma; IGF 1R; MiR 122; Sorafenib

Indexed keywords

MICRORNA; MICRORNA 122; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; PICROPODOPHYLLIN; PRECLAMOL; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SORAFENIB; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IGF1R PROTEIN, HUMAN; MIRN122 MICRORNA, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SOMATOMEDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; 3' UNTRANSLATED REGION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CARCINOMA, HEPATOCELLULAR; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIVER NEOPLASMS; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; TIME FACTOR; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NEOPLASTIC STEM CELLS; NIACINAMIDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RAF KINASES; RAS PROTEINS; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962030408     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.034     Document Type: Article

References (44)

1. Bruix J., Llovet J.M. HCC surveillance: who is the target population?. Hepatology 2003, 37:507-509.
2. Huo T.I., Wu J.C., Lee S.D. Comparison of staging systems for HCC: one more positive answer or mission impossible?. Hepatology 2005, 42:238-239.
3. Villanueva A., Minguez B., Forner A., Reig M., Llovet J.M. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu. Rev. Med 2010, 61:317-328.
4. Vitale A., Volk M.L., Pastorelli D., Lonardi S., Farinati F., et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010, 51:165-173.
5. Shen Y.C., Hsu C., Cheng A.L. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J. Gastroenterol 2010, 45:794-807.
6. Palmer D.H. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med 2008, 359:2498-2499.
7. Johnson P., Billingham L. Sorafenib for liver cancer: the horizon broadens. Lancet Oncol 2009, 10:4-5.
8. Tejeda-Maldonado J., García-Juárez I., Aguirre-Valadez J., González-Aguirre A., Vilatobá-Chapa M., Armengol-Alonso A., et al. Diagnosis and treatment of hepatocellular carcinoma: an update. World J. Hepatol 2015, 7:362-376.
9. Villanueva A., Llovet J.M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res 2012, 18:1824-1826.
10. Rudalska R., Dauch D., Longerich T., McJunkin K., Wuestefeld T., Kang T.W., et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med 2014, 20:1138-1146.
11. Xin H.W., Ambe C.M., Hari D.M., Wiegand G.W., Miller T.C., Chen J.Q., et al. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut 2013, 62:1777-1786.
12. Berasain C. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?. Gut 2013, 62:1674-1675.
13. Engelman J.A., Jänne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res 2008, 14:2895-2899.
14. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
15. Ryu J.Y., Kim H.U., Lee S.Y. Human genes with a greater number of transcript variants tend to show biological features of housekeeping and essential genes. Mol. Biosyst 2015, 11:2798-2807.
16. Davidson-Moncada J., Papavasiliou F.N., Tam W. MicroRNAs of the immune system: roles in inflammation and cancer. Ann. N. Y. Acad. Sci 2010, 1183:183-194.
17. Shenouda S.K., Alahari S.K. MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev 2009, 28:369-378.
18. Rao X., Leva G.D., Li M., Fang F., Devlin C., Hartman-Frey C., et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2010, 30:1082-1097.
19. Liu K., Liu S., Zhang W., Ji B., Wang Y., Liu Y. miR222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma. Int. J. Oncol 2014, 45:1537-1546.
20. Song L., Li Y., Li W., Wu S., Li Z. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting p-type adenosine triphosphatase A (ATP7A). J. Cell. Biochem 2014, 115:1234-1242.
21. Mao K., Zhang J., He C., Xu K., Liu J., Sun J., et al. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett 2014, 352:245-252.
22. Chang J., Guo J.T., Jiang D., Guo H., Taylor J.M., Block T.M. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J. Virol 2008, 82:8215-8223.
23. Blanc V., Park E., Schaefer S., Miller M., Lin Y., Kennedy S., et al. Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver. Genome Biol 2014, 15:R79.
24. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem 2006, 99:671-678.
25. Xu H., He J.H., Xiao Z.D., Zhang Q.Q., Chen Y.Q., Zhou H., et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010, 52:1431-1442.
26. Tsai W.C., Hsu P.W., Lai T.C., Chau G.Y., Lin C.W., Chen C.M., et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49:1571-1582.
27. Coulouarn C., Factor V.M., Andersen J.B., Durkin M.E., Thorgeirsson S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009, 28:3526-3536.
28. Xu Y., Xia F., Ma L., Shan J., Shen J., Yang Z., et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011, 310:160-169.
29. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
30. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
31. Cortés-Sempere M., de Miguel M.P., Pernía O., Rodriguez C., de Castro Carpeño J., Nistal M., et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene 2013, 32:1274-1283.
32. Ma L., Liu J., Shen J., Liu L., Wu J., Li W., et al. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol. Ther 2010, 9:554-561.
33. Casa A.J., Dearth R.K., Litzenburger B.C., Lee A.V., Cui X. The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front. Biosci 2008, 13:3273-3287.
34. Tao Y., Pinzi V., Bourhis J., Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway - therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol 2007, 4:591-602.
35. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8:915-928.
36. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
37. Navarro M., Baserga R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 2001, 142:1073-1081.
38. Rahman M., Hasan M.R. Cancer metabolism and drug resistance. Metabolites 2015, 5:571-600.
39. Spinzi G., Paggi S. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med 2008, 359:2497-2498.
40. Kurata T., Tamura K., Kaneda H., Nogami T., Uejima H., Asai G.G., et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann. Oncol 2004, 15:173-174.
41. Moriceau G., Hugo W., Hong A., Shi H., Kong X., Yu C.C., et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015, 27:240-256.
42. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009, 69:1951-1957.
43. Shan J., Shen J., Liu L., Xia F., Xu C., Duan G., et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 2012, 56:1004-1014.
44. Morgillo F., Cascone T., Aiuto E.D., Martinelli E., Troiani T., Saintigny P., et al. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br. J. Cancer 2011, 105:382-392.